Document Type: Research Articles
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Department of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
It has been shown that a 4-bp insertion/deletion (ins/del) polymorphism of EGLN2 influences the risk of several
cancers. However, to date, no study has inspected the impact of the 4-bp ins/del polymorphism on breast cancer (BC)
risk. A case-control study, including 134 breast cancer patients and 154 healthy women, was here conducted to examine
the possible association between EGLN2 4-bp ins/del polymorphism and BC risk in a southeast Iranian population.
A mismatched polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was designed for
genotyping of the variant. Our findings did not support any association between the 4-bp ins/del polymorphism and
the risk of BC in the codominant, dominant, recessive and allele inheritance models tested. When links between
the EGLN2 4-bp ins/del polymorphism and clinicopathological characteristics of the patients were evaluate the variant
was only associated with HER2 status. More studies with larger sample sizes and diverse ethnicities are warranted to
verify our finding.